Precede Biosciences ESMO 2026: Plasma Profiling Identifies Molecular States Predicting PSMA Therapy Outcomes

The Quick Take

• Precede Biosciences presented ESMO 2026 data showing plasma profiling identifies three molecular states predicting response to PSMA-directed radioligand therapy in advanced prostate cancer.
• The research identified androgen receptor-high and stem/epithelial molecular states via liquid biopsy, previously only characterized through tissue sampling techniques.
• PSMA radioligand therapy is an emerging modality for advanced prostate cancer with significant commercial potential as adoption grows across oncology practices globally.

Precede Biosciences has presented data at ESMO 2026 demonstrating that baseline plasma profiling can identify distinct molecular states in advanced prostate cancer patients that predict response to PSMA-directed radioligand therapy. The research identified three molecular states — including androgen receptor-high/metabolic and stem/epithelial profiles — previously characterized in tissue samples, now confirmed via liquid biopsy techniques. The ability to predict therapeutic response and resistance through non-invasive plasma testing represents a significant advance in precision oncology for prostate cancer, with direct commercial implications for companion diagnostic testing and treatment selection protocols across oncology practices globally.

The commercial implications of predictive biomarkers for PSMA-directed radioligand therapy extend across multiple industry stakeholders. Radioligand therapy developers including Novartis's Pluvicto program and Bristol Myers Squibb and AstraZeneca oncology pipelines could license or partner with Precede Biosciences if its predictive plasma profiling technology achieves regulatory clearance as a companion diagnostic. Companion diagnostics command premium pricing in oncology — often $1,000 to $3,000 per test — making validated predictive biomarker platforms significant revenue opportunities for bioscience companies able to demonstrate clinical utility at conferences of ESMO and ASCO standing.

The forward signal is whether Precede Biosciences advances from ESMO conference presentation to clinical validation studies and ultimately FDA/EMA submission for companion diagnostic clearance alongside a PSMA-directed therapy. The timeline from conference presentation to regulatory submission typically spans three to five years, dependent on funding, partnership support, and study enrollment speed. The macro variable governing the thesis is prostate cancer incidence trends and penetration of radioligand therapy in clinical practice — broader adoption of PSMA-targeted treatment creates a larger addressable market for Precede's predictive diagnostics. Watch major pharma partnership announcements and subsequent ESMO or ASCO abstract acceptances for validation progress.

Synthesized from 1 source.